Tonix Pharmaceuticals Holding Corp.
NASDAQ:TNXPBiotechnology
-$0.24 today
- Market cap
- $54.80M
- Beta
- 1.68
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$10.75
Volume 1.04M
Average 0.49M
TNXP Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Tonix Pharmaceuticals Holding Corp.NASDAQ: TNXP
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $555K rose 12.6% year over year, ahead of the -26.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 13.7% from the prior quarter. Over 3 fiscal years it compounded at +15.4% a year.
Context
- Depreciation & amortization amounted to 14.7% of revenue in FY2025, down 19.2 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +12.6% holds above the trailing-twelve-month pace of -26.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 1.93M USD
- Year-over-year change
- -43.7%
- 4-year CAGR
- +149.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.93M | -43.7% |
| FY2024 | 2024-12-31 | 3.42M | -20.3% |
| FY2023 | 2023-12-31 | 4.29M | +242.5% |
| FY2022 | 2022-12-31 | 1.25M | +2406.0% |
| FY2021 | 2021-12-31 | 50K | — |
Depreciation & Amortization vs competitors
How TNXP compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -26.5% is the 8th highest of 10, against a peer median of +0.4%.
- Depreciation & amortization amounts to 11.3% of revenue for TNXP, versus a peer median of 197.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $12.49M USD | -28.5% | -12.3% | 197.7% | |
| LTM Mar 2026 | $9.23M USD | +0.4% | +51.6% | — | |
| FY2025 | €5.09M EUR | +155.3% | -51.8% | 182.7% | |
| LTM Mar 2026 | $5.03M USD | +1.0% | -14.6% | 438.9% | |
| LTM Mar 2026 | $1.99M USD | -26.5% | +15.4% | 11.3% | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $1.14M USD | -2.3% | +2.2% | — |
| LTM Mar 2026 | $226K USD | -16.3% | +27.5% | 383.1% | |
| LTM Mar 2026 | $143K USD | +37.5% | +8.6% | 8.0% | |
| LTM Mar 2026 | $81K USD | -69.3% | -5.7% | — | |
| LTM Mar 2026 | $70K USD | +62.8% | +21.1% | — | |
| Peer median (excluding TNXP) | — | +0.4% | +2.2% | 197.7% | |
Competitors are the stored peer set for TNXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 7.77M | 10.09M | 13.11M |
| Cost of Revenue | 0 | 0 | 4.74M | 7.77M | 8.57M |
| Gross Profit | 0 | 0 | 3.03M | 2.33M | 4.54M |
| Gross Margin | — | — | 39.0% | 23.1% | 34.7% |
| Research & Development | 68.84M | 81.88M | 86.66M | 40.45M | 44.49M |
| Selling, General & Admin | 23.47M | 30.22M | 34.75M | 40.1M | 85.76M |
| Operating Expenses | 92.31M | 112.09M | 121.41M | 139.03M | 130.25M |
| Depreciation & Amortization | 50K | 1.25M | 4.29M | 3.42M | 1.93M |
| EBITDA | (92.24M) | (108.97M) | (112.37M) | (74.32M) | (122.01M) |
| EBITDA Margin | — | — | -1446.5% | -736.3% | -930.9% |
| Operating Income | (92.31M) | (112.09M) | (118.38M) | (136.7M) | (125.7M) |
| Operating Margin | — | — | -1523.9% | -1354.3% | -959.1% |
| Interest Income | 25K | 1.87M | 0 | 0 | 4.15M |
| Interest Expense | 0 | 0 | 0 | 0 | 89K |
| Other Income / Expenses | 25K | 1.87M | 1.72M | 6.67M | 1.68M |
| Income Before Tax | (92.29M) | (110.22M) | (116.66M) | (130.04M) | (124.02M) |
| Pre-Tax Margin | — | — | -1501.8% | -1288.3% | -946.2% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (92.29M) | (110.22M) | (116.66M) | (130.04M) | (124.02M) |
| Net Margin | — | — | -1501.8% | -1288.3% | -946.2% |
| EPS (Basic) | (163,968.00) | (811.68) | (6,368.84) | (176.60) | (14.57) |
| EPS (Diluted) | (163,968.00) | (811.68) | (6,368.84) | (176.60) | (14.57) |
| Weighted Avg Shares | 563 | 3.07M | 1.83M | 2.26M | 8.51M |
| Weighted Avg Shares (Diluted) | 563 | 3.07M | 1.83M | 2.26M | 8.51M |
Tonix Pharmaceuticals Holding Corp.
NASDAQ:TNXP
Intrinsic Alpha fair value
Locked
Current Price
$2.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.